MRNS Annual EBITDA
-$125.50 M
-$120.16 M-2251.45%
31 December 2023
Summary:
As of January 23, 2025, MRNS annual earnings before interest, taxes, depreciation & amortization is -$125.50 million, with the most recent change of -$120.16 million (-2251.45%) on December 31, 2023. During the last 3 years, it has fallen by -$58.36 million (-86.92%). MRNS annual EBITDA is now -11629.79% below its all-time high of -$1.07 million, reached on December 31, 2012.MRNS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRNS Quarterly EBITDA
-$20.25 M
+$10.82 M+34.83%
30 September 2024
Summary:
As of January 23, 2025, MRNS quarterly earnings before interest, taxes, depreciation & amortization is -$20.25 million, with the most recent change of +$10.82 million (+34.83%) on September 30, 2024. Over the past year, it has increased by +$17.10 million (+45.78%). MRNS quarterly EBITDA is now -126.01% below its all-time high of $77.83 million, reached on September 30, 2022.MRNS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRNS TTM EBITDA
-$122.86 M
+$8.34 M+6.36%
30 September 2024
Summary:
As of January 23, 2025, MRNS TTM earnings before interest, taxes, depreciation & amortization is -$122.86 million, with the most recent change of +$8.34 million (+6.36%) on September 30, 2024. Over the past year, it has increased by +$2.64 million (+2.10%). MRNS TTM EBITDA is now -13245.32% below its all-time high of -$920.60 thousand, reached on March 31, 2013.MRNS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRNS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2251.4% | +45.8% | +2.1% |
| 3 y3 years | -86.9% | +29.9% | -2202.0% |
| 5 y5 years | -238.7% | +29.9% | -2202.0% |
MRNS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2251.4% | at low | -126.0% | +45.8% | -3872.1% | +6.4% |
| 5 y | 5-year | -2251.4% | at low | -126.0% | +45.8% | -3872.1% | +6.4% |
| alltime | all time | <-9999.0% | at low | -126.0% | +45.8% | <-9999.0% | +6.4% |
Marinus Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.25 M(-34.8%) | -$122.86 M(-6.4%) |
| June 2024 | - | -$31.07 M(-9.1%) | -$131.20 M(+1.5%) |
| Mar 2024 | - | -$34.19 M(-8.4%) | -$129.26 M(+3.0%) |
| Dec 2023 | -$125.50 M(+2251.5%) | -$37.35 M(+30.6%) | -$125.50 M(+7.2%) |
| Sept 2023 | - | -$28.59 M(-1.9%) | -$117.05 M(+1001.0%) |
| June 2023 | - | -$29.14 M(-4.2%) | -$10.63 M(-41.5%) |
| Mar 2023 | - | -$30.43 M(+5.3%) | -$18.18 M(+240.6%) |
| Dec 2022 | -$5.34 M(-94.4%) | -$28.90 M(-137.1%) | -$5.34 M(+72.6%) |
| Sept 2022 | - | $77.83 M(-312.2%) | -$3.09 M(-96.9%) |
| June 2022 | - | -$36.68 M(+108.6%) | -$99.67 M(+15.4%) |
| Mar 2022 | - | -$17.58 M(-34.0%) | -$86.37 M(-9.9%) |
| Dec 2021 | -$95.84 M(+42.7%) | -$26.66 M(+42.3%) | -$95.84 M(+10.7%) |
| Sept 2021 | - | -$18.74 M(-19.9%) | -$86.56 M(+3.8%) |
| June 2021 | - | -$23.39 M(-13.6%) | -$83.41 M(+10.3%) |
| Mar 2021 | - | -$27.06 M(+55.7%) | -$75.61 M(+12.3%) |
| Dec 2020 | -$67.14 M(+24.0%) | -$17.38 M(+11.5%) | -$67.32 M(+3.0%) |
| Sept 2020 | - | -$15.59 M(-0.0%) | -$65.33 M(+2.8%) |
| June 2020 | - | -$15.59 M(-16.9%) | -$63.56 M(+5.2%) |
| Mar 2020 | - | -$18.77 M(+22.0%) | -$60.41 M(+11.6%) |
| Dec 2019 | -$54.14 M(+46.1%) | -$15.39 M(+11.4%) | -$54.14 M(+10.5%) |
| Sept 2019 | - | -$13.82 M(+11.1%) | -$48.99 M(+5.7%) |
| June 2019 | - | -$12.44 M(-0.5%) | -$46.37 M(+6.7%) |
| Mar 2019 | - | -$12.50 M(+22.1%) | -$43.47 M(+17.3%) |
| Dec 2018 | -$37.05 M | -$10.24 M(-8.5%) | -$37.05 M(+17.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$11.19 M(+17.4%) | -$31.46 M(+28.8%) |
| June 2018 | - | -$9.54 M(+56.8%) | -$24.42 M(+26.2%) |
| Mar 2018 | - | -$6.08 M(+30.9%) | -$19.35 M(+4.0%) |
| Dec 2017 | -$18.61 M(-33.9%) | -$4.65 M(+11.9%) | -$18.61 M(-6.3%) |
| Sept 2017 | - | -$4.15 M(-7.0%) | -$19.88 M(-9.9%) |
| June 2017 | - | -$4.47 M(-16.4%) | -$22.06 M(-16.5%) |
| Mar 2017 | - | -$5.34 M(-9.5%) | -$26.41 M(-6.2%) |
| Dec 2016 | -$28.16 M(+15.6%) | -$5.91 M(-6.8%) | -$28.16 M(-5.3%) |
| Sept 2016 | - | -$6.34 M(-28.1%) | -$29.73 M(+5.3%) |
| June 2016 | - | -$8.82 M(+24.4%) | -$28.24 M(+14.9%) |
| Mar 2016 | - | -$7.09 M(-5.3%) | -$24.57 M(+0.8%) |
| Dec 2015 | -$24.36 M(+127.5%) | -$7.49 M(+54.7%) | -$24.37 M(+19.3%) |
| Sept 2015 | - | -$4.84 M(-6.1%) | -$20.43 M(+18.6%) |
| June 2015 | - | -$5.15 M(-25.2%) | -$17.23 M(+12.1%) |
| Mar 2015 | - | -$6.89 M(+94.1%) | -$15.37 M(+37.9%) |
| Dec 2014 | -$10.71 M(+107.2%) | -$3.55 M(+116.8%) | -$11.14 M(+24.0%) |
| Sept 2014 | - | -$1.64 M(-50.3%) | -$8.98 M(+4.8%) |
| June 2014 | - | -$3.29 M(+23.6%) | -$8.57 M(+24.0%) |
| Mar 2014 | - | -$2.66 M(+91.5%) | -$6.91 M(+33.7%) |
| Dec 2013 | -$5.17 M(+383.1%) | -$1.39 M(+13.7%) | -$5.17 M(+36.8%) |
| Sept 2013 | - | -$1.22 M(-25.3%) | -$3.78 M(+47.8%) |
| June 2013 | - | -$1.64 M(+77.7%) | -$2.56 M(+177.7%) |
| Mar 2013 | - | -$920.60 K | -$920.60 K |
| Dec 2012 | -$1.07 M | - | - |
FAQ
- What is Marinus Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Marinus Pharmaceuticals?
- What is Marinus Pharmaceuticals annual EBITDA year-on-year change?
- What is Marinus Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Marinus Pharmaceuticals?
- What is Marinus Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Marinus Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Marinus Pharmaceuticals?
- What is Marinus Pharmaceuticals TTM EBITDA year-on-year change?
What is Marinus Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of MRNS is -$125.50 M
What is the all time high annual EBITDA for Marinus Pharmaceuticals?
Marinus Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.07 M
What is Marinus Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, MRNS annual earnings before interest, taxes, depreciation & amortization has changed by -$120.16 M (-2251.45%)
What is Marinus Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of MRNS is -$20.25 M
What is the all time high quarterly EBITDA for Marinus Pharmaceuticals?
Marinus Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $77.83 M
What is Marinus Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, MRNS quarterly earnings before interest, taxes, depreciation & amortization has changed by +$17.10 M (+45.78%)
What is Marinus Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of MRNS is -$122.86 M
What is the all time high TTM EBITDA for Marinus Pharmaceuticals?
Marinus Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$920.60 K
What is Marinus Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, MRNS TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.64 M (+2.10%)